title: [Chemotherapy with cisplatin, adriamycin, etoposide and ifosfamide in microcytic lung carcinoma].
abstract: BACKGROUND
  The aim of this study was to analyze the results obtained in the treatment of small cell lung cancer (SCLC) with the PAVI chemotherapy protocol (cisplatin, adriamycin, etoposide and ifosfamide).
  
  
  METHODS
  Over a period of 3 years, 41 patients with a mean age of 57 years were treated. Twenty-two patients were considered as having limited disease (LD) and 19 disseminated disease (DD). Survival was studied by the Kaplan and Meier method.
  
  
  RESULTS
  The percentage of complete response (CR) achieved was 42%, LD 52% and 27% for DD, with partial responses (PR) being achieved in 50%, 43% in LD and 60% in DD. With a mean follow up of 32 months, the mean 2 length of response was 13 months in the patients with CR and 9 months in those with PR. The median of survival in LD was 22 months and 10 months for patients with DD. Prolonged survival of over 2 years, was only achieved in LD (16%). Five patients died in relation with the treatment. Hematologic toxicity was doses-limited with the greatest toxicity being found in patients with DD under the Karnofsky index (KI).
  
  
  CONCLUSIONS
  The PAVI protocol is effective in the treatment of small cell lung cancer and a good median of survival may be achieved in patients with limited disease. Toxicity is elevated and is fundamentally found in patients with disseminated disease and under the Karnofsky index, with its use not being recommended in these cases.
authors.affiliation: Servicio de Oncología Médica, Hospital General Gregorio Marañón, Madrid.
authors.forename: R
authors.initials: R
authors.lastname: García Gómez
authors.forename: R
authors.initials: R
authors.lastname: García Arroyo
authors.forename: A
authors.initials: A
authors.lastname: Meana García
authors.forename: P
authors.initials: P
authors.lastname: Martínez del Prado
authors.forename: R
authors.initials: R
authors.lastname: González del Val
authors.forename: G
authors.initials: G
authors.lastname: Pérez Manga
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
chemical_list: D005047:Etoposide; D004317:Doxorubicin; D002945:Cisplatin; D007069:Ifosfamide
vernacular_title: Quimioterapia con cisplatino, adriamicina, etopósido e ifosfamida en el carcinoma microcítico pulmonar.